Dimethyl fumarate reduces the frequency and function of inflammatory immune cells in relapsing-remitting multiple sclerosis patients

被引：0
|
作者：
Diaz, G. Montes [1 ,2 ,3 ]
Fraussen, J. [1 ,2 ,3 ]
Van Wijmeersch, B. [1 ,2 ,3 ,4 ]
Hupperts, R. [5 ,6 ]
Somers, V. [1 ,2 ,3 ]
机构：
[1] Univ Limburg, Biomed Res Inst, Maastricht, Netherlands
[2] Univ Limburg, Transnat, Maastricht, Netherlands
[3] Hasselt Univ, Sch Life Sci, Diepenbeek, Belgium
[4] Rehabil & MS Ctr, Overpelt, Belgium
[5] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Neurosci, Maastricht, Netherlands
[6] Zuyderland Med Ctr, Acad MS Ctr Limburg, Sittard, Netherlands
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1169
引用
收藏
页码：616 / 617
页数：2
相关论文
共 50 条
  • [31] Clinical characteristics of relapsing-remitting multiple sclerosis patients with persistent lymphopenia with dimethyl fumarate and comparison with no lymphopenic patients
    Lopez Ruiz, R.
    Eichau, S.
    Perez Gamez, M.
    Navarro Mascarell, G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Izquierdo, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 921 - 922
  • [32] Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis
    Urshansky, Nataly
    Mausner-Fainberg, Karin
    Auriel, Eitan
    Regev, Keren
    Bornstein, Natan M.
    Karni, Arnon
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 232 (1-2) : 171 - 178
  • [33] Comparing the impact of dose titration on gastrointestinal tolerability: diroximel fumarate versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
    Naismith, R. T.
    Badwan, R.
    Chen, H.
    Lyons, J.
    Miller, C.
    Scaramozza, M.
    Shankar, S. L.
    Antezana, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 587 - 588
  • [34] Dimethyl Fumarate: A Review in Relapsing-Remitting MS
    Hannah A. Blair
    Drugs, 2019, 79 : 1965 - 1976
  • [35] Effectiveness of fingolimod, dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis: a comparative longitudinal study
    Kalincik, T.
    Spelman, T.
    Jokubaitis, V.
    Horakova, D.
    Havrdova, E.
    Izquierdo, G.
    Prat, A.
    Girard, M.
    Duquette, P.
    Lugaresi, A.
    Grammond, P.
    Alroughani, R.
    Lechner-Scott, J.
    Prevost, J.
    Terzi, M.
    Grand'Maison, F.
    Boz, C.
    Trojano, M.
    Van Wijmeersch, B.
    Pucci, E.
    Granella, F.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    McCombe, P.
    Solaro, C.
    Van Pesch, V.
    Ozakbas, S.
    Slee, M.
    Spitaleri, D.
    Sanchez-Menoyo, J. L.
    Ampapa, R.
    Hodgkinson, S.
    Karabudak, R.
    Vucic, S.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 325 - 327
  • [36] Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis
    Kappos, Ludwig
    Giovannoni, Gavin
    Gold, Ralf
    Fox, Robert
    Phillips, J. Theodore
    Hotermans, Christophe
    Zhang, Annie
    Viglietta, Vissia
    Miller, David
    NEUROLOGY, 2013, 80
  • [37] An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis
    Valencia-Sanchez, Cristina
    Carter, Jonathan L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (12) : 1399 - 1405
  • [38] Safety and efficacy of dimethyl fumarate in a real-world relapsing-remitting multiple sclerosis population
    Barros, A.
    Sequeira, J.
    Sousa, A.
    Capela, C.
    Pedrosa, R.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 877 - 878
  • [39] Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
    Karl E. Carlström
    Ewoud Ewing
    Mathias Granqvist
    Alexandra Gyllenberg
    Shahin Aeinehband
    Sara Lind Enoksson
    Antonio Checa
    Tejaswi V. S. Badam
    Jesse Huang
    David Gomez-Cabrero
    Mika Gustafsson
    Faiez Al Nimer
    Craig E. Wheelock
    Ingrid Kockum
    Tomas Olsson
    Maja Jagodic
    Fredrik Piehl
    Nature Communications, 10
  • [40] Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
    Dubey, Duvyanshu
    Kieseier, Bernd C.
    Hartung, Hans P.
    Hemmer, Bernhard
    Warnke, Clemens
    Menge, Til
    Miller-Little, William A.
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (04) : 339 - 346
12345